Mangel AW, Wang J, Sherrill B, Gnanasakthy A, Ervin C, Fehnel SE. Urgency as an endpoint in irritable bowel syndrome. Gastroenterology Research. 2011 Feb 1;4(1):9-12.
Grogan S, Hartley L, Fry G, Conner M, Gough B. Appearance concerns and smoking in young men and women: going beyond weight control. Drug-Educ Prev Polic. 2010 May 6;17(3):261-9. doi: 10.3109/09687630802422019
Varadhachary GR, Edmonston TB, Karanth S, Carlson HR, Lebanony D, Rosenwald S, Lenzi R, Spector Y, Cohen D, Raber MN. Prospective gene signature study using microrna to predict the tissue of origin (ToO) in patients with cancer of unknown primary (CUP). Poster presented at the 2010 ASCO meeting; May 2010. [abstract] J Clin Oncol. 2010 May; 28(Suppl 15).
Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol. 2008 Feb 20;26(6):925-33.
Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005 Jun 1;23(16):3668-75.
Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005 May 1;23(13):2946-54.
Smith T, Hillner B, Neighbors DM, McSorley P, LeChevalier T. An economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol. 1995;13(9):2166-73. doi: 10.1200/JCO.1995.13.9.2166.